Will NKTR-102 Specific Biomarkers Translate To A Survival Advantage? Roth Capital Comments
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price target, following presentation at the San Antonio Breast Cancer Symposium (SABC).
Chattopadhyay explained, “At the SABC meeting data on target-specific biomarkers from Circulating Tumor Cell (CTC), in patients with advanced breast cancer was presented. These biomarkers can predict response to topoisomerase-1 inhibition as well measure chemo-sensitivity. Unfortunately, published data on the Ki67 is retrospective, in the neoadjuvant setting, and conflicted on the correlation between Ki67 the choice of chemotherapy and survival benefit. This limits generalization to the BEACON study, in our view.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 4.5% and a 48.6% success rate. Chattopadhyay has a 7.5% average return when recommending NKTR, and is ranked #961 out of 3412 analysts.